Fig. 1 | British Journal of Cancer

Fig. 1

From: Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

Fig. 1

Pharmacokinetic profile of eribulin-LF. Mean plasma concentration–time curves of eribulin by dose of eribulin-LF on a linear scale and log-linear scale (a) and individual AUC versus eribulin-LF dose in Schedule 1 and Schedule 2 (b)—patients with DLTs are highlighted in red. AUC(I) area under the curve (infinity), DLT dose-limiting toxicity, LF liposomal formulation

Back to article page